The Journal of Heart and Lung Transplantation
Volume 29, Issue 12 , Pages 1395-1404 , December 2010

Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: A single-center experience

  • Anthony De Soyza, PhD, MbChB

      Affiliations

    • Transplantation and Immunobiology Group, Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK
    • Corresponding Author InformationReprint requests: Anthony De Soyza, PhD, MbChB, Transplantation and Immunology Group, Newcastle University, Institute of Cellular Medicine, High Heaton, Newcastle-upon-Tyne NE7 7DN, UK. Telephone: 00-44-191-2137468. Fax: 00-44-191-2137087
    • ,
  • Gerard Meachery, MBBCh, MRCP

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • Katy L.M. Hester, MBBS

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • Audrey Nicholson, MSc

      Affiliations

    • Department of Medical Microbiology, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • Gareth Parry, FRCP

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • Krzysztof Tocewicz, FRCS

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • Thasee Pillay, MbChB, FCS(CTh)FRCS

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • Stephen Clark, FRCS

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • James L. Lordan, FRCP

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • Stephan Schueler, MD, PhD, FRCS

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • Andrew J. Fisher, MBBS, PhD, FRCP

      Affiliations

    • Transplantation and Immunobiology Group, Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK
    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • John H. Dark, FRCS

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • F. Kate Gould, FRC(Path)

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • Department of Medical Microbiology, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • Paul A. Corris, FRCP

      Affiliations

    • Transplantation and Immunobiology Group, Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK
    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK

References 

  1. Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology. 2007;153:917–923
  2. Mahenthiralingam E, Vandamme P. Taxonomy and pathogenesis of the Burkholderia cepacia complex. Chronic Respir Dis. 2005;2:209–217
  3. Govan JR, Brown AR, Jones AM. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol. 2007;2:153–164
  4. Lipuma JJ. Update on the Burkholderia cepacia complex. Curr Opin Pulmon Med. 2005;11:528–533
  5. Liou TG, Woo MS, Cahill BC. Lung transplantation for cystic fibrosis. Curr Opin Pulmon Med. 2006;12:459–463
  6. Hosenpud JD, Bennett LE, Keck BM, et al. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet. 1998;351:24–27
  7. Husain S, Singh N. Burkholderia cepacia infection and lung transplantation. Sem Respir Infect. 2002;17:284–290
  8. de Perrot M, Chaparro C, McRae K, et al. Twenty-year experience of lung transplantation at a single center: influence of recipient diagnosis on long-term survival. J Thorac Cardiovasc Surg. 2004;127:1493–1501
  9. Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis; outcome following lung transplantation. Am J Respir Crit Care Med. 2001;163:43–48
  10. Mariencheck WI, Palmer SM, Tapson VF, et al. Survival following lung transplantation of cystic fibrosis patients colonized with Burkholderia cepacia. Am J Respir Crit Care Med. 2000;161:720
  11. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:745–755
  12. Mahenthiralingam E, Bischof B, Byrne SK, et al. DNA-based diagnostic approaches for the identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III. J Clin Microbiol. 2000;38:3165–3173
  13. De Soyza A, McDowell A, Archer L, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet. 2001;358:1780–1781
  14. Aris RM, Routh JC, LiPuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex (Survival linked to genomovar type). Am J Respir Crit Care Med. 2001;164:2102–2106
  15. De Soyza A, Morris K, McDowell A, et al. Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation. Thorax. 2004;59:526–528
  16. Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation. 2008;85:771–774
  17. Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in cystic fibrosis patients colonized with Burkholderia cepacia complex: results from two French centers. Thorax. 2008;63:732–737
  18. Perry JD, Riley G, Johnston S, et al. Activity of disinfectants against Gram-negative bacilli isolated from patients undergoing lung transplantation for cystic fibrosis. J Heart Lung Transplant. 2002;21:1230–1231
  19. Ledson MJ, Gallagher MJ, Robinson M, et al. A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia. J Aerosol Med. 2002;15:51–57
  20. Andrews JM. BSAC standardized disc susceptibility testing method (version 5). J Antimicrob Chemother. 2006;58:511–529
  21. Aaron SD, Ferris W, Henry DA, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med. 2000;161:1206–1212
  22. Lang BJ, Aaron SD, Ferris SW, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2000;162:2241–2245
  23. Estenne M, Maurer J, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2001;21:297–310
  24. Meachery G, De Soyza A, Nicholson A, et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax. 2008;63:725–731
  25. Govan JR, Brown PH, Maddison J, et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet. 1993;342:15–19
  26. Govan JR. Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex. J R Soc Med. 2000;38:40–45
  27. Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis. 2001;33:1469–1475
  28. Chen JS, Witzmann KA, Spilker T, et al. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr. 2001;139:643–649
  29. Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984;104:206–210
  30. Pitt TL, Kaufmann ME, Patel PS, et al. Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol. 1996;44:203–210
  31. Blackburn L, Brownlee K, Conway S, et al. ‘Cepacia syndrome' with Burkholderia multivorans, 9 years after initial colonization. J Cystic Fibros. 2004;3:133–134
  32. Webb AK, Egan J. Should patients with cystic fibrosis infected with Burkholderia cepacia undergo lung transplantation?. Thorax. 1997;52:671–673
  33. Egan JJ, McNeil K, Bookless B, et al. Post-transplantation survival of cystic fibrosis patients infected with Pseudomonas cepacia. Lancet. 1994;344:552–553
  34. Murray S, Charbeneau J, Marshall BC, et al. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:363–371
  35. Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant. 2008;8:1025–1030
  36. Aaron SD. Antibiotic sensitivity testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. Paediatr Respir Rev. 2007;8:256–261
  37. Aaron SD, Vandemheen KL, Ferris W, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet. 2005;366:463–471
  38. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2008;CD006961
  39. Foweraker JE, Laughton CR, Brown DF, et al. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob Agents Chemother. 2009;53:4809–4815
  40. Foweraker JE, Laughton CR, Brown DF, et al. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbations of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother. 2005;55:921–927

PII: S1053-2498(10)00370-0

doi: 10.1016/j.healun.2010.06.007

The Journal of Heart and Lung Transplantation
Volume 29, Issue 12 , Pages 1395-1404 , December 2010

Article Tools

* Image Usage & Resolution